Revenue missed analyst estimates by 7.0%. Earnings per share (EPS) exceeded analyst estimates by 21%. Looking ahead, revenue ...

The company ended the quarter with $192 million in cash and equivalents, enough to fund operations past 2027. 2seventy Bio ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

TD Cowen analyst Yaron Werber maintained a Hold rating on 2seventy bio (TSVT – Research Report) today. The company’s shares closed ...

Good day and thank you for standing by. Welcome to the 2seventy bio Third Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. After the speakers ...

2Seventy Bio, Inc. ( (TSVT)) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its investors. 2seventy bio, Inc. is a biotechnology company ...

When combined with the significant progress our team has made in streamlining our cost structure, 2seventy continues to make meaningful progress on our goal of achieving breakeven operations ...

Shares of 2seventy bio were trading at $4.73 as of November 07. Over the last 52-week period, shares are up 107.46%. Given that these returns are generally positive, long-term shareholders should be ...

2seventy bio Stock Performance NASDAQ TSVT opened at $4.73 on Friday. The stock has a market cap of $243.60 million, a price-to-earnings ratio of -1.54 and a beta of 1.78. The business has a 50 ...